Cerebral revascularization after the Carotid Occlusion Surgery Study: what candidates remain, and can we do better?

Timothy G. White, MD,1 Hussam Abou-Al-Shaar, MD,1 Jung Park, MD, PhD,1 Jeffrey Katz, MD,2 David J. Langer, MD,2 and Amir R. Dehdashti, MD1,2

Departments of 1Neurosurgery and 2Neurology, North Shore University Hospital, Barbara and Donald Zucker School of Medicine at Hofstra Northwell; and 2Department of Neurosurgery, Lenox Hill Hospital, Barbara and Donald Zucker School of Medicine at Hofstra Northwell, Manhasset, New York

OBJECTIVE Cerebral revascularization for carotid occlusion was previously a mainstay procedure for the cerebrovascular neurosurgeon. However, the 1985 extracranial-intracranial bypass trial and subsequently the Carotid Occlusion Surgery Study (COSS) provided level 1 evidence via randomized controlled trials against bypass for symptomatic atherosclerotic carotid occlusion disease. However, in a small number of patients optimal medical therapy fails, and some patients with flow-limiting stenosis develop a perfusion-dependent neurological examination. Therefore it is necessary to further stratify patients by risk to determine who may most benefit from this intervention as well as to determine perioperative morbidity in this high-risk patient population.

METHODS A retrospective review was performed of all revascularization procedures done for symptomatic atherosclerotic cerebrovascular steno-occlusive disease. All patients undergoing revascularization after the publication of the COSS in 2011 were included. Perioperative morbidity and mortality were assessed as the primary outcome to determine safety of revascularization in this high-risk population. All patients had documented hypoperfusion on hemodynamic imaging.

RESULTS A total of 35 revascularization procedures were included in this review. The most common indication was for patients with recurrent strokes, who were receiving optimal medical therapy and who suffered from cerebrovascular steno-occlusion. At 30 days only 3 perioperative ischemic events were observed, 2 of which led to no long-term neurological deficit. Immediate graft patency was good, at 94%. Long term, no further strokes or ischemic events were observed, and graft patency remained high at 95%. There were no factors associated with perioperative ischemic events in the variables that were recorded.

CONCLUSIONS Cerebral revascularization may be done safely at high-volume cerebrovascular centers in high-risk patients in whom optimal medical therapy has failed. Further research must be done to develop an improved methodology of risk stratification for patients with symptomatic atherosclerotic cerebrovascular steno-occlusive disease to determine which patients may benefit from intervention. Given the high risk of recurrent stroke in certain patients, and the fact that patients fail medical therapy, surgical revascularization may provide the best method to ensure good long-term outcomes with manageable up-front risks.

https://thejns.org/doi/abs/10.3171/2018.11.FOCUS18536

KEYWORDS COSS; Carotid Occlusion Surgery Study; carotid occlusion; cerebral bypass; cerebral revascularization
disease of the intracranial vasculature, or for symptomatic cerebral atherosclerotic stenosis and occlusion. However, historical and recent randomized clinical trials have whittled down the indications for bypass in the setting of cerebrovascular atherosclerotic steno-occlusive disease.

The first trial, published in the New England Journal of Medicine in 1985, showed no benefit for cerebral revascularization in patients with symptomatic moyamoya vasculopathy; however, it failed to stratify patients by risk in order to determine which would receive the greatest benefit from intervention. Subsequently, the St. Louis Carotid Occlusion Study (STLCOS) was able to identify patients at the highest risk for recurrent stroke in the setting of cerebrovascular stenosis and occlusion by using PET oxygen extraction fraction (OEF). The COSS was then designed on this premise. In order to determine whether patients with symptomatic cerebral atherosclerotic stenosis and occlusion who are at the highest risk of recurrent stroke would benefit from revascularization, patients in the COSS underwent PET OEF in order to stratify them by risk. They were then randomized to best medical therapy versus surgical revascularization. Despite numerous criticisms, the ultimate outcome showed that surgical revascularization provided no benefit over best medical therapy, mostly due to the impressive natural history of medical therapy and the perioperative surgical risk associated with revascularization. That being said, more recent studies still demonstrate that misery perfusion is a predictor of stroke risk in patients with symptomatic atherosclerotic cerebrovascular steno-occlusive disease, even with newer optimal medical management.

A small group of patients develop ischemic symptoms and symptomatic hypoperfusion (limb shaking and/or crescendo transient ischemic attacks [TIAs] or orthostatic hypoperfusion) even on optimal medical therapy, due to severe hemodynamic impairment. This group of patients has not been well studied by prior trials. There is little literature on their clinical syndrome and subsequent outcome and surgical risk after undergoing revascularization. The purpose of this study was to identify this group of patients and discuss their surgical outcomes in a single institution’s series.

Methods

A retrospective chart review of all patients who underwent cerebral revascularization for symptomatic cerebral atherosclerotic stenosis and occlusion between January 2011 and August 2018 was done. All patients who underwent cerebral revascularization for nonmoyamoya vasculopathy were included in the study. This study was approved by the IRB at the Feinstein Institute under the Northwell Health System. Clinical and demographic data were collected for each patient. Variables studied included patient age, sex, diagnosis, medical history, clinical course, medical therapy, preoperative imaging, postoperative imaging, and postoperative clinical outcomes. Independent radiologists determined bypass patency. Clinical outcomes were gathered from date of last patient follow-up in the medical record. Of particular concern was the perioperative morbidity associated with individual cases; therefore, 30-day outcomes were collected as the primary surgical outcome in these patients.

Patient Choice and Surgical Technique

Patients were identified as possible candidates for cerebral revascularization if they showed evidence of atherosclerotic carotid or middle cerebral artery (MCA) steno-occlusive disease and optimal medical therapy had failed, or if they had perfusion-dependent neurological examinations. Optimal medical therapy including dual-antiplatelet therapy (DAPT), tight blood pressure control, glycemic control, and statin use was determined by the stroke neurologist taking care of the individual patients and was documented as part of the data that were collected. Once identified as possible candidates, the patients underwent conventional cerebral angiography for diagnostic purposes, to determine the site of disease, and for presurgical planning. All patients also underwent some form of hemodynamic imaging, including either SPECT with and without Diamox, quantitative MRA (QMRI) noninvasive optimal vessel analysis (NOVA), MR perfusion, or CT perfusion. SPECT was done to determine those patients with impaired cerebrovascular reserve (CVR), and QMRI NOVA was used as an adjunct demonstrating decreased flow in the vascular territory in question.

Surgery was subsequently performed teamed with a trained neuroanesthesiologist and with strict blood pressure control. Direct superficial temporal artery (STA)-MCA bypass was preferred in all cases because the goal in each procedure was flow augmentation. Postoperatively, patients were followed after 30 days had passed postdischarge in order to accurately assess perioperative morbidity. Postprocedure bypass patency was assessed using digital subtraction angiography, CT angiography (CTA), or QMRI NOVA.

Perioperative management focused on tight blood pressure controls and adherence to an aspirin regimen as well as patient positioning. During the case, systolic blood pressure was maintained above 120 mm Hg during the procedure, especially for induction. Postoperative blood pressure goals depended on graft flow but generally were from 120 to 140 mm Hg. Patients were placed on aspirin (81 mg) prior to the procedure, given aspirin (325 mg) on the night of the procedure, and then continued on 81 mg daily. CTA was done on postoperative day 1. If any patient developed a new deficit on examination, MRI and QMRI NOVA studies were done to assess for hyperperfusion versus new stroke.

Statistical Analysis

All data were collected and stored via a REDcap (Research Electronic Data Capture) database, and statistics were analyzed using SPSS and Excel. All variables are expressed as the average ± SD, and where appropriate p = 0.05 was used for statistical significance. For descriptive statistics the average was calculated. Univariate (Student t-test and chi-square analysis for continuous variable) and multivariate regression were used to predict factors associated with bypass patency and clinical outcome.
**Results**

**Patient Demographics**

In total, 36 patients underwent cerebral revascularization for nonmoyamoya cerebrovascular occlusive disease. One of the 36 patients was not included in the study because the cerebrovascular occlusion and subsequent hypoperfusion was secondary to carotid sacrifice during head and neck surgery. The average patient age was 55 years (range 22–74 years). All patients except 1 were on at least single-antiplatelet therapy prior to presentation. Clinical presentation included recurrent strokes, recurrent TIA, perfusion-dependent examination, hemorrhagic transformation of stroke, and headache with severe hypoperfusion. The most common presentation was recurrent stroke in 74% (26/35) of patients, followed by recurrent TIA in 11% (4/35), and perfusion-dependent examination in 9% (3/35). Both hemorrhagic transformation of stroke as well as headache and severe hypoperfusion occurred in 1 patient each. Of note, most patients presented with metabolic syndrome including the combination of hypertension, hyperlipidemia, and insulin resistance. There were 3 unique cases in which patients did not present with classic symptoms of atherosclerosis: one patient with fibromuscular dysplasia, one with sickle cell anemia, and one with antiphospholipid syndrome.

**Imaging Characteristics**

All patients were evaluated using multimodal imaging techniques. During the workup, patients underwent MRI followed by vessel imaging. In 57% (20/35) of patients MRI results demonstrated multiple watershed-area infarcts, which was the most frequent MRI finding, whereas other patients presented with multiple MCA but no watershed area strokes. All patients underwent some form of hemodynamic imaging. Most commonly the imaging workup included QMRA NOVA as well as SPECT with and without Diamox. QMRA NOVA was done in 60% (21/35) of patients, and in 100% (35/35) of those patients flow-limiting stenosis was demonstrated when compared to historical age-based normal values. SPECT was done in 91% of patients (32/35), and of those patients 81% (26/32) showed decreased CVR when challenged with Diamox. All patients without diminished CVR who received Diamox did not improve with the administration of the drug, and at baseline had severe hypoperfusion on SPECT along with recurrent stroke on optimal medical therapy. Patients were categorized as having internal carotid artery (ICA) steno-occlusion, bilateral ICA steno-occlusion, or MCA steno-occlusion. ICA steno-occlusion was the most common, occurring in 49% of patients (17/35), followed by recurrent stroke on optimal medical therapy. Patients were categorized as having internal carotid artery (ICA) steno-occlusion, bilateral ICA steno-occlusion, or MCA steno-occlusion. ICA steno-occlusion was the most common, occurring in 49% of patients (17/35), followed by MCA steno-occlusion in 31% (Table 1).

**Perioperative Outcomes**

Thirty-day perioperative outcomes were assessed in all patients to accurately determine perioperative morbidity in this theoretically high-risk population. Immediate postoperative graft occlusion occurred in 2 patients; therefore immediate graft patency was 94% (33/35). Postoperative complications occurred in 11% of patients (4/35). There were 3 cases of postoperative ischemic events (9% of patients), which were permanent in only 1 case. Further description of these 3 events can be seen in Table 2. All events occurred in patients who underwent multiple MCA but no watershed area strokes. All patients underwent some form of hemodynamic imaging. Most commonly the imaging workup included QMRA NOVA as well as SPECT with and without Diamox. QMRA NOVA was done in 60% (21/35) of patients, and in 100% (35/35) of those patients flow-limiting stenosis was demonstrated when compared to historical age-based normal values. SPECT was done in 91% of patients (32/35), and of those patients 81% (26/32) showed decreased CVR when challenged with Diamox. All patients without diminished CVR who received Diamox did not improve with the administration of the drug, and at baseline had severe hypoperfusion on SPECT along with recurrent stroke on optimal medical therapy. Patients were categorized as having internal carotid artery (ICA) steno-occlusion, bilateral ICA steno-occlusion, or MCA steno-occlusion. ICA steno-occlusion was the most common, occurring in 49% of patients (17/35), followed by MCA steno-occlusion in 31% (Table 1).
curred within 3 days postoperatively. There was also 1 case of postoperative seizure treated successfully with antiepileptic drugs. One patient with postoperative graft occlusion underwent a subsequent encephaloduroarteriosynangiosis (EDAS) procedure when postoperative angiography demonstrated the occlusion. In univariate and multivariate analysis no factors (age, sex, preoperative hemodynamic imaging findings, site of occlusion) were identified as being associated with the risk of a perioperative ischemic event or the likelihood of bypass patency (p > 0.05).

**Long-Term Outcomes**

Long-term clinical outcomes were assessed in 80% (28/35) of patients, whereas long-term graft patency outcomes were assessed in 60% (21/35) of patients. Bypass grafts were found to be patent in 95% of patients (20/21) (Table 2). In one patient who experienced immediate graft failure on long-term follow-up the graft was found to be open, and in the other patient with immediate occlusion who underwent the revision EDAS procedure long-term patency was not assessed. Clinically, no patient experienced subsequent stroke; however, 1 patient did develop a persistent seizure disorder postoperatively. Duration of follow-up was on average 25.5 months (range 3–84 months).

**Illustrative Cases**

**Case 1**

A 58-year-old man with a history of stroke, TIA, hyper-tension, hyperlipidemia, and atrial fibrillation who was on coumadin and DAPT presented to the hospital with left facial droop, hand weakness, and numbness. MRI revealed right MCA territory acute infarcts and angiography demonstrated right ICA occlusion with no filling of the right ICA (Fig. 1A and B). QMRA NOVA demonstrated right ICA occlusion with a small amount of collateral flow from the right posterior communicating artery, and follow-up SPECT with Diamox challenge revealed right-sided hypoperfusion with decreased CVR (Fig. 1C). Given the imaging evidence of right-sided hypoperfusion as well as recurrent strokes on DAPT, a right-sided STA-MCA flow augmentation revascularization was offered and, after a discussion of the risks and benefits, the patient chose to undergo the procedure. Postoperatively the patient experienced no complications, with postoperative imaging showing a patent bypass graft (Fig. 1D). One year after the initial bypass the patient had no further evidence of stroke.

**Case 2**

A 60-year-old woman presented with aphasia and right-sided weakness. MRI revealed left-sided basal ganglia and watershed zone infarcts as well as prior watershed ischemic changes (Fig. 2A). CTA and conventional angiography showed 95% left MCA stenosis, so the patient was placed on an aspirin and Plavix regimen. However, 1 week later she presented back to the hospital with worsening right-sided weakness and recurrence of aphasia after initial improvement from prior admission. Follow-up MRI showed new strokes (Fig. 2B and C). QMRA NOVA
showed low flow in the left anterior cerebral artery (ACA) and left MCA, and SPECT with Diamox showed significant left-sided hypoperfusion with diminished CVR (Fig. 2D). Due to recurrence of stroke and hemodynamic compromise the patient underwent left-sided STA-MCA by-pass. Postoperatively the patient experienced no complications and the graft was patent immediately and 1 year postoperatively based on QMRA NOVA (Fig. 2E). At 5 years postbypass the patient had not experienced another stroke.

**Discussion**

Prior randomized controlled trials have demonstrated no benefit to surgical revascularization in patients with symptomatic cerebrovascular atherosclerotic steno-occlusive disease. However, optimal medical management, which includes optimization of atherosclerotic and stroke risk factors as well as DAPT, still fails to prevent strokes in a small number of patients. These patients may present with perfusion-dependent examinations or recurrent TIAs and/or strokes. No randomized controlled trial has investigated the role of bypass in this patient group. Although the COSS did stratify patient risk by using hemodynamic imaging modalities, it did not specifically investigate patients in whom best medical therapy failed.

The purpose of this retrospective analysis was to demonstrate the safety and perioperative risks associated with revascularization in theoretically high-risk patients in whom medical management has failed and who showed definitive impaired cerebrovascular reserve. Here we demonstrate that when done at a high-volume cerebrovascular center with specified neuroanesthesia, this procedure can be done with a reasonable level of morbidity and may represent an effective salvage procedure in certain patients. In this series perioperative ischemic events occurred in 9% of patients (3/35), with only 1 patient developing an irreversible neurological deficit.

The original 1985 extracranial-intracranial bypass trial randomized 137 patients with symptomatic carotid or intracranial steno-occlusive disease but failed to stratify patients by risk prior to randomization. Ultimately, no benefit was found with surgical intervention at an average follow-up of 55.8 months, with stroke rates in the medical arm of 29% versus 31% in the surgical arm. Following the publication of these results, validated criteria for cerebral hemodynamic impairment were developed via the STLCOS. At that time, studies on bypass hemodynamics demonstrated that revascularization was able to correct impaired hemodynamics in patients. That being said, the increased OEF used to randomize patients in the COSS may not have been an adequate predictor of hemodynamic impairment.

The STLCOS established that PET OEF was able to predict stroke risk in patients with symptomatic cerebrovascular steno-occlusive disease and stage II hemodynamic impairment. In patients with misery perfusion and increased OEF, the stroke risk approached 26.5% at 2 years, compared to 5.6% in patients without impaired perfusion, which led to a predicted benefit of 40% when developing the COSS and determined patient number to power the study. However, in the medical arm of the
COSS the stroke risk amounted to 22% over the 2-year study period, with the medical arm faring far better than predicted. Given that the predicted stroke risk used for the COSS was based on studies done in the 1990s, further studies have investigated whether, with newer medical therapy, misery perfusion still predicts stroke risk. More recently, Yamauchi et al. demonstrated that misery perfusion on PET OEF still predicts increased stroke risk in patients with symptomatic cerebrovascular steno-occlusive disease. The authors established that even with the most recent optimal medical management, increased OEF alone (as used in STLCOS and COSS) leaves patients at increased risk of stroke. Therefore, stricter management of these patients is required, and there may still be a role for revascularization in these highest-risk patients. In this study we mainly used SPECT imaging combined with a Diamox challenge in order to perform risk stratification in patients with hypoperfusion and to determine which patients have decreased cerebrovascular reserve.

Ultimately, it was not the goal of this series to validate diagnostic criteria. However, all patients were selected to be possible candidates for bypass based on their clinical presentation combined with hemodynamic imaging in the form of SPECT with and without Diamox, QMRA NOVA, MR perfusion, or CT perfusion. Therefore, further studies would be justified to define the optimal modality to determine impaired cerebral hemodynamics and define misery perfusion.

The outcomes of the COSS were driven by two main factors: the impressively good outcomes of the medically managed patients and the perioperative morbidity of revascularization surgery. Perioperative stroke risk in the COSS was 14%, which was similar to that of the original extracranial-intracranial bypass trial, and these perioperative ischemic events made up the majority of stroke risk in this study group. Once past the initial perioperative period the surgical patients maintained a significantly lower stroke risk than those in the medical arm. Therefore, decreasing perioperative morbidity and ensuring operative safety is important going forward. In this series we demonstrate that at a high-volume center with specialized neuroanesthesia, perioperative risk in high-risk patients was maintained at less than 10%. Analysis of the COSS data predicted that to show benefit, surgical risk would need to be roughly 50% of what it was. That being said, this patient population should be considered somewhat separate from the COSS population because, for reasons that have been previously discussed, optimal medical therapy had failed.

Indeed, although the indications for cerebral revascularization for patients with symptomatic steno-occlusive cerebrovascular disease have waned after the publication of the COSS, they have not gone away altogether. However, literature addressing the individual patient populations that may benefit the most has waned as well. This series represents a unique assessment of perioperative risk in high-risk patients not clearly addressed by the COSS. Clearly, further research into this patient group is warranted in order to assess the risk of further stroke after initial therapy as well as to determine optimal treatment modalities.

Conclusions

Cerebral revascularization for non moyamoya symptomatic steno-occlusive cerebrovascular disease has not been shown to provide clinical benefit, but remains an effective and safe option as rescue therapy in patients in whom conventional medical therapy alone has failed. However, this should only be practiced at high-volume centers with specialized staff and experienced surgeons.

References


Disclosures

The authors report no conflict of interest concerning the materi-
als or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: all authors. Acquisition of data: White, Abou-Al-Shaar, Park. Analysis and interpretation of data: White. Drafting the article: White. Critically revising the article: White, Dehdashti. Reviewed submitted version of manuscript: White, Langer, Dehdashti. Approved the final version of the manuscript on behalf of all authors: White. Statistical analysis: White. Administrative/technical/material support: Abou-Al-Shaar. Study supervision: Katz, Langer, Dehdashti.

Correspondence
Timothy G. White: North Shore University Hospital, Barbara and Donald Zucker School of Medicine at Hofstra Northwell, Manhasset, NY. twhite7@northwell.edu.